Mqx-503    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
51Scleroderma6

51. Scleroderma    [ 466 clinical trials,   536 drugs,   (DrugBank: 142 drugs),   110 drug target genes,   210 drug target pathways]
Searched query = "Scleroderma", "Systemic sclerosis", "SSc", "dcSSc", "lcSSc"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
6 / 466 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00577304
(ClinicalTrials.gov)
December 200718/12/2007A Study of a Topical Form of Nitroglycerin and Placebo in the Treatment and Prevention of Raynaud's PhenomenonA Study of a Topical Formulation of Nitroglycerin, MQX-503, and Matching Vehicle in the Treatment and Prevention of Raynaud's PhenomenonRaynaud's Disease;Raynaud's Disease Secondary to Scleroderma;Raynaud's Disease Secondary to Other Autoimmune DiseaseDrug: Nitroglycerin;Drug: Topical AmphiMatrixMediQuest TherapeuticsNULLActive, not recruiting15 Years70 YearsBoth200Phase 3United States
2NCT00419419
(ClinicalTrials.gov)
December 20064/1/2007Phase III Study of a Topical Gel Formulation for Treatment and Prevention of Raynaud's PhenomenonPhase III In-Life Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, and Matching Placebo Gel in the Treatment and Prevention of Raynaud's PhenomenonRaynaud's Disease;Scleroderma;Autoimmune DiseasesDrug: Topical AmphiMatrix with nitroglycerin (MQX-503)MediQuest TherapeuticsNULLCompleted18 Years70 YearsBoth80Phase 3United States;Sweden;United Kingdom
3EUCTR2005-004979-37-GB
(EUCTR)
27/11/200618/09/2006 Phase III In-Life” Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, and Matching Placebo Gel in the Treatment and Prevention of Raynaud’s Phenomenon - 06-004 A2 Phase III In-Life” Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, and Matching Placebo Gel in the Treatment and Prevention of Raynaud’s Phenomenon - 06-004 A2 Moderate to severe primary Raynaud’s, OR patients with Raynaud’s phenomenon secondary to autoimmune diseases, such as sclerodermaMediQuest Therapeutics, Inc.NULLNot Recruiting Female: yes
Male: yes
100Phase 3United Kingdom;Sweden
4EUCTR2005-004979-37-SE
(EUCTR)
27/10/200608/09/2006Phase III In-Life” Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, and Matching Placebo Gel in the Treatment and Prevention of Raynaud’s Phenomenon - 06-004 A2Phase III In-Life” Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, and Matching Placebo Gel in the Treatment and Prevention of Raynaud’s Phenomenon - 06-004 A2 Moderate to severe primary Raynaud’s,OR patients with Raynaud’s phenomenon secondary to autoimmune diseases, such as sclerodermaProduct Name: MQX-503
Product Code: MQX-503
INN or Proposed INN: 10% Nitroglycerine in Propylene Glycol, USP
Other descriptive name: Nitroglycerine gel
MediQuest Therapeutics, Inc.NULLNot RecruitingFemale: yes
Male: yes
100Phase 3United Kingdom;Sweden
5NCT00378521
(ClinicalTrials.gov)
July 200618/9/2006Dose Response Study of a Topical Gel for the Treatment of Raynaud's PhenomenonPhase II Dose Response Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, in the Treatment of Raynaud's PhenomenonRaynaud's Disease;Raynaud's Disease Secondary to Scleroderma;Raynaud's Disease Secondary to Autoimmune DiseaseDrug: MQX-503MediQuest TherapeuticsNULLCompleted18 Years75 YearsBoth15Phase 2United States
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT00253331
(ClinicalTrials.gov)
November 200413/11/2005Lab Study of MQX-503 in Treatment of Raynaud'sPhase III Laboratory Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, in the Treatment of Raynaud’s PhenomenonRaynaud Disease;Raynaud Disease Secondary to Scleroderma;Raynaud Secondary to Other Autoimmune DiseaseDrug: topical organogel with nitroglycerinMediQuest TherapeuticsNULLCompleted18 Years80 YearsBoth36Phase 2;Phase 3United States